A6797512
PHA-848125 , ≥98% , 802539-81-7
| Pack Size | Price | Stock | Quantity |
| 1MG | RMB399.20 | In Stock |
|
| 5MG | RMB1383.20 | In Stock |
|
| 10MG | RMB2028.00 | In Stock |
|
| 50MG | RMB5935.20 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 190 °C |
| Density | 1.33 |
| storage temp. | Store at -20°C |
| solubility | ≥23.05 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O |
| form | solid |
| pka | 14.44±0.40(Predicted) |
| color | Light yellow to yellow |
| InChIKey | RXZMYLDMFYNEIM-UHFFFAOYSA-N |
| SMILES | N1=C2C(CC(C)(C)C3C(C(NC)=O)=NN(C)C=32)=CN=C1NC1=CC=C(N2CCN(C)CC2)C=C1 |
Description and Uses
PHA-848125 is an ATP-competitive inhibitor of cyclin-dependent kinases (Cdks) that potently inhibits Cdk2/cyclin A (IC50 = 45 nM). It is at least 3-fold less potent at Cdks 1, 3, 4, 5, and 7. PHA-848125 is orally available and displays efficacy in suppressing the growth of cancer cells or tumor xenografts in animals.
PHA-848125 is a cyclin dependent kinase (CDK) inhibitor. Oral PHA-848125 showed antitumor activity via dual targeting of cyclin-dependent kinase and tropomyosin receptor kinase families in human carcinoma cell and xenografted mouse model of carcinoma.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P280-P305+P351+P338 |
